



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: HIROYUKI KISHINO et al.

Serial No. 10/567,269 ✓

Filed: February 6, 2006

For: IMIDAZOPYRIDINE DERIVATIVES

Art Unit: --

Examiner: --

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97**

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By

Date

4/18/06

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

RELATED APPLICATION		
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE

If this is inconvenient, additional copies will be submitted upon request.

6. In accordance with 37 C.F.R. 1.97, (check one)

- ☒ the attached information is filed within three months of the filing date of the captioned case.
- ☐ the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
- ☐ the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
- ☐ the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application *and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.*
- ☐ no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.

Respectfully submitted,



By: CATHERINE D. FITCH

Attorney _____ For Applicant(s)

Reg. No. 36,502

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-4283

Date: April 18, 2006

COMPLETE IF KNOWN

Application Number	10/567,269
---------------------------	------------

Filing Date	February 6, 2006
--------------------	------------------

First Named Inventor	Hiroyuki Kishino et al.
-----------------------------	-------------------------

Group Art Unit	--
----------------	----

Examiner Name	--
---------------	----

Attorney Docket Number	BY0030P
------------------------	---------

1 of 2

[illegible]

Examiner Initials*	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number Kind Code (if known)		
			JP2001-226269	Takeda Chemical Industries, Ltd.	08/21/2001
			JP2003-313126	Sankyo Co. Ltd.	11/06/2003
			WO 02/094799	Neurogen Corporation	11/28/2002
			WO 2005/040157	Eli Lilly and Company	05/06/2005
			WO 01/21577	Takeda Chemical Industries, Ltd.	03/29/2001
			WO 02/42273	Bristol-Myers Squibb Company	05/30/2002
			WO 2005/035526	Argenta Discovery Ltd.	04/21/2005
			WO 2005/019240	Amgen, Inc.	03/03/2005

/Niloofer Rahmani/

07/23/2008

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

STATEMENT BY APPLICANT

use as many sheets as necessary)

2

of

2

10/567.269

February 6, 2006

Hirovuki Kishino et al.

— 2 —

—

BY0030P

NON PATENT LITERATURE DOCUMENTS

Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

/Niloofer Rahmani/

07/23/2008

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/